Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Allegheny General Hospital Among Nation's Top Enrollment Sites for Clinical Trial Exploring How Wearable Technology Can Inform Therapies for Atrial Fibrillation Patients


News provided by

Allegheny Health Network

Oct 03, 2024, 14:30 ET

Share this article

Share toX

Share this article

Share toX

Trial Participants Wear Apple Smartwatches to Determine if Prescribed Blood Thinner Medication Can Be Stopped for Daily Use
Trial Participants Wear Apple Smartwatches to Determine if Prescribed Blood Thinner Medication Can Be Stopped for Daily Use

Clinical Trial Participants Wear Apple Smartwatches to Determine if Prescribed Blood Thinner Medication Can Be Stopped for Daily Use

PITTSBURGH, Oct. 3, 2024 /PRNewswire-PRWeb/ -- Allegheny General Hospital (AGH), the flagship academic medical center of Allegheny Health Network (AHN), is among the nation's top enrollment sites for a clinical trial exploring how an Apple™ smartwatch can be used to tailor daily oral anticoagulants (blood thinners) in certain patient populations diagnosed with atrial fibrillation (Afib).

The REACT-AF trial, which stands for "Rhythm Evaluation from AntiCoagulaTion with Continuous Monitoring of Atrial Fibrillation," is led by researchers at Johns Hopkins Medicine and is funded by the National Institutes of Health.

"We're extremely pleased to be one of the most active participants in this groundbreaking trial that blends new, wearable technology with fundamental principles of medication management," said Amit Thosani, MD, Director of the Mario Lemieux Center for Heart Rhythm Disorders at AHN.

Post this

The trial randomizes half of the enrollees to wear Apple smartwatches for 14 hours per day; watches are paired to patient iPhones and pre-programmed with a software that monitors irregular heart rhythms. If patients can go 30 consecutive days without an episode of erratic heart beats lasting longer than one hour, they are then able to stop their anticoagulant medication under clinical supervision. The other half of patients continue blood thinners without interruption.

REACT-AF aims to understand if short term use of blood thinners may be just as safe and effective for patients with infrequent Afib episodes, compared to continuous use.

"Although taking blood thinners daily is known to lower stroke risk in Afib patients, they are also associated with an increase in bleeding complications. The purpose of this trial is to better understand how to personalize anticoagulation safely and effectively, especially for patients with isolated atrial fibrillation episodes," said Amit Thosani, MD, principle lead of the trial at AGH and Director of the Mario Lemieux Center for Heart Rhythm Disorders at AHN. "We're extremely pleased to be one of the most active participants in this groundbreaking trial that blends new, wearable technology with fundamental principles of medication management."

AFib is an irregular, often rapid heart rhythm that originates in the top chambers of the heart, reducing blood flow, increasing the risk of stroke and causing symptoms including palpitations, shortness of breath, and fatigue. Afib slows overall blood flow, allowing clots to form in the heart which can then travel to the brain increasing the likelihood of stroke.

In many cases, anticoagulants may be the best treatment for stroke prevention but they have been associated with an increased risk of bleeding.

Launched in July 2023, REACT-AF is a randomized, blinded endpoint trial that aims to enroll 5,350 participants across roughly 100 US study sites.

Participation for patients will last up to five years where eligible participants are randomized to either the control group who stays on their blood thinner for the study, or the experimental group who receives an Apple Watch that continuously monitors for AFib every 15 minutes and stops their blood thinner.

To be eligible for the study, patients must be between 22 and 85 years old, have a history of AFib, have an iPhone, and be at a low to moderate risk for stroke.

"The use of smartwatches is an exciting advance in cardiovascular medicine – not only do they help clinicians make more informed decisions for therapeutic approaches, but they also give patients more agency to take control of their life and in turn, improve their overall health and well-being," said Stephen Bailey, MD, cardiothoracic surgeon and Chair of AHN Cardiovascular Institute.

"We are extremely proud of Dr. Thosani and his remarkable team for their tireless work in this trial, and at a higher level, for their dedication to improving the care of complex cardiovascular diseases," concluded Dr. Bailey.

In May, representatives from the Mario Lemieux Foundation and Highmark Health announced a $5 million commitment to the Network's nationally-recognized cardiac electrophysiology (EP) program, formally establishing "The Mario Lemieux Center for Heart Rhythm Care" at AHN. The investment will continue to advance the Center's academic and research priorities, including AI solutions, clinical trials, and provider education.

REACT-AF is just one of 13 active clinical trials currently taking place at the Center.

Media Contact

Nikki Buccina, Allegheny Health Network, 412-596-2679, [email protected], www.ahn.org

SOURCE Allegheny Health Network

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.